Japanese Pharmas Need To Get More Global
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese firms need to change strategy to become competitive with U.S., European firms, biotech exec says in interview with "The Pink Sheet" DAILY during the BioInvestor Forum in San Francisco.
You may also be interested in...
Roche Adds To Oncology Lexicon With BRAF Kinase Deal
Plexxikon’s PLX-4032 could eventually compete against biologics in the colorectal cancer market.
U.S./Japan Free Trade Agreement Would Encourage Pharma Innovation, Lilly CEO Says
CEO Taurel argues in favor of an open market that would ease Japan-specific clinical trial requirements.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.